For its fourth fiscal quarter (ending December 31), Amicus Therapeutics Inc (NASDAQ: FOLD) has reported a -145% decline in E.P.S. from $-0.11 a year ago to $0.05 in the current quarter. For the latest four quarters through December 31, E.P.S. were $-0.18 versus $-0.51 for the same period a year ago — a decline of -65%.
Recent Price Action
Amicus Therapeutics Inc (NASDAQ: FOLD) stock declined by -2.9% on 2/19/25. The shares closed at $9.56. Moreover, trading volume in this decline was unusually high at 198% of normal. The stock has been weak relative to the market over the last nine months and has declined -0.8% during the last week.
Current PriceTarget Research Rating
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Amicus Therapeutics has a poor Power Rating of 27 and a very low Appreciation Score of 14, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment